Charles Fortier, PhD is an Expert Researcher in Drug Product Development at Adocia in Lyon, France, where he has been contributing since 2015. With over ten years of experience in CMC drug product formulation and in physical chemistry, Charles has supported the development of insulin and weight management peptides-based co-formulations from early-stage research through Phase 2 clinical trials. He specializes in difficult-to-formulate peptide combinations, and biophysical strategies to enhance drug stability and pharmacokinetics. Charles has played a pivotal role in cross-functional collaborations across pharmacology, regulatory affairs, physical chemistry, chemistry and analytical science. He has also been in charge of CMC sections in regulatory submissions (INDs and IMPDs) and driven successful tech transfers and manufacturing readiness for clinical-stage programs with our trusted CDMO partners. Charles is actively involved in proprietary formulation technology evaluation with academic and industry partners. His research interests include biophysical characterization of biologics, higher-order structural analysis, fate of the peptide after subcutaneous delivery, and the integration of knowledge management to accelerate the conversion of innovation into products. He brings a multidisciplinary background and an investigational mindset in drug product development and is passionate about solving complex formulation issues.